INAL RESEARCH Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study

被引:5
|
作者
Kang, D. -W. [1 ]
Park, S. -K. [2 ]
Yu, Y. L. [3 ]
Lee, Y. [4 ]
Lee, D. H. [5 ]
Kang, S. [3 ,6 ,7 ,8 ]
机构
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea
[2] Catholic Univ Korea, Coll Pharm, Bucheon, South Korea
[3] Natl Canc Ctr, Ctr Gynecol Canc, Res Inst & Hosp, Goyang, South Korea
[4] Natl Canc Ctr, Dept Internal Med, Goyang, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[6] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, Goyang, South Korea
[7] Natl Canc Ctr, Res Inst & Hosp, Ctr Gynecol Canc, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
[8] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
关键词
next-generation sequencing; single-gene testing; non-small-cell lung cancer; distant metastasis; real-world evidence;
D O I
10.1016/j.esmoop.2023.102200
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Despite the growing use of next-generation sequencing (NGS) in the management of advanced non-smallcell lung cancer (NSCLC), there is little evidence that its use leads to improved clinical outcomes. This study aimed to compare the effectiveness of NGS with that of single-gene testing (SGT) alone in patients with advanced NSCLC. Materials and methods: This was a retrospective cohort study conducted on patients diagnosed with advanced lung adenocarcinoma between 2017 and 2018 from a nationwide, population-based database. We identified patients who had SGT exclusively (SGT group) or underwent upfront NGS or NGS following SGT as an initial evaluation (NGS group). Patients were followed up until death or the end of the study (31 December 2019). The adjusted hazard ratio (aHR) for death was estimated using the Cox proportional hazards model. The factors affecting the adoption of NGS were identified. Results: Of 8566 patients diagnosed with advanced lung adenocarcinoma, 402 and 6932 patients were assigned to the NGS and SGT groups, respectively. More NGS was carried out in younger patients, those with higher incomes, and those living in urban areas. After balancing these confounders through matching, no difference was observed in the median overall survival and risk of death between the NGS and SGT groups [18.5 versus 19.7 months, log-rank P 1/4 0.783; aHR 0.98, 95% confidence interval (CI) 0.84-1.14, respectively]. Only in a subgroup for whom epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitors were not indicated, NGS was associated with better survival outcomes (14.1 versus 9.0 months, log-rank P 1/4 0.006; aHR 0.82, 95% CI 0.69-0.97). Conclusions: In the real world, NGS for all-comers in patients with advanced NSCLC did not increase survival outcomes. When health care resources to support equal access to NGS are limited, upfront SGT followed by NGS may be a more efficient strategy
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer
    Ying-Qiang Lu
    Kai-Hua Lu
    慢性疾病与转化医学(英文), 2017, 3 (01) : 1 - 7
  • [2] Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients
    Takeyasu, Yuki
    Yoshida, Tatsuya
    Motoi, Noriko
    Teishikata, Takashi
    Tanaka, Midori
    Matsumoto, Yuji
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Kakishima, Hiroki
    Tsuchida, Takaaki
    Yamamoto, Noboru
    Ohe, Yuichiro
    Yatabe, Yasushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (07) : 1114 - 1122
  • [3] The rational application of liquid biopsy based on next-generation sequencing in advanced non-small cell lung cancer
    Zhao, Chenglong
    Li, Jianghua
    Zhang, Yongchang
    Han, Rui
    Wang, Yubo
    Li, Li
    Zhang, Yimin
    Zhu, Mengxiao
    Zheng, Jie
    Du, Haiwei
    Hu, Chen
    Zhou, Chengzhi
    Yang, Nong
    Cai, Shangli
    He, Yong
    CANCER MEDICINE, 2023, 12 (05): : 5603 - 5614
  • [4] Cost-effectiveness of next-generation sequencing for advanced EGFR/ ALK-negative non-small cell lung cancer
    Kang, Dong-Won
    Park, Sun-Kyeong
    Kang, Sokbom
    Lee, Eui-Kyung
    LUNG CANCER, 2024, 197
  • [5] Clinical Next-Generation Sequencing in Patients with Non-Small Cell Lung Cancer
    Hagemann, Ian S.
    Devarakonda, Siddhartha
    Lockwood, Christina M.
    Spencer, David H.
    Guebert, Kalin
    Bredemeyer, Andrew J.
    Al-Kateb, Hussam
    Nguyen, TuDung T.
    Duncavage, Eric J.
    Cottrell, Catherine E.
    Kulkarni, Shashikant
    Nagarajan, Rakesh
    Seibert, Karen
    Baggstrom, Maria
    Waqar, Saiama N.
    Pfeifer, John D.
    Morgensztern, Daniel
    Govindan, Ramaswamy
    CANCER, 2015, 121 (04) : 631 - 639
  • [6] Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer
    Yu, Tiffany M.
    Morrison, Carl
    Gold, Edward J.
    Tradonsky, Alison
    Arnold, Renee J. G.
    VALUE IN HEALTH, 2018, 21 (11) : 1278 - 1285
  • [7] Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer
    Matsuda, Hiroyuki
    Ogawa, Toru
    Sadatsuki, Yasunari
    Tsujino, Toshiaki
    Wada, Shingo
    Kim, Seok-Won
    Hatanaka, Yutaka
    RESPIRATORY INVESTIGATION, 2023, 61 (01) : 61 - 73
  • [8] Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing
    El Zaitouni, Sara
    Laraqui, Abdelilah
    Ghaouti, Meriem
    Benzekri, Asmae
    Kettani, Fouad
    Boustany, Youssra
    Benmokhtar, Soukaina
    Alaoui, Hafsa Lamrani
    El Annaz, Hicham
    Abi, Rachid
    Tagajdid, Mohamed Rida
    El Kochri, Safae
    El Mchichi, Bouchra
    Bouaiti, El Arbi
    Lahlou, Idriss Amine
    El Hassani, Rabii Ameziane
    Ennibi, Khalid
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [9] Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group
    Malapelle, Umberto
    Delle Donne, Alessandro
    Pagni, Fabio
    Fraggetta, Filippo
    Rocco, Elena Guerini
    Pasello, Giulia
    Perrone, Giuseppe
    Pepe, Francesco
    Vatrano, Simona
    Pignata, Sandro
    Pinto, Carmine
    Pruneri, Giancarlo
    Russo, Antonio
    Parra, Hector J. Soto
    Vallone, Stefania
    Marchetti, Antonio
    Troncone, Giancarlo
    Novello, Silvia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 193
  • [10] The Utility of Next-Generation Sequencing in the Treatment Decision-Making for Metastatic Non-Small-Cell Lung Cancer
    Orlov-Slavu, Maria Cristina
    Popa, Ana Maria
    Tulin, Adrian
    Stoian, Anca Pantea
    Poiana, Catalina
    Paleru, Cristian
    Calu, Valentin
    Nitipir, Cornelia
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (08)